Perspectives in Thoracic Oncology recently underwent a rebranding. The meeting’s new name, Personalized Therapies in Thoracic Oncology, comes with a fresh agenda, based on EGFR, ROS1, ALK, KRAS/BRAF, and other emerging biomarkers. The content will be geared towards providing practical considerations for the use of immune checkpoint inhibitors and new immuno-oncology combination therapies.
The change comes on the heels of advances in treatment options, making a one-size fits all approach, no longer the best path for today’s lung cancer patient. Out-dated, cookie-cutter treatment methods remain the focus of many of today’s CME conferences, but Personalized Therapies in Thoracic Oncology goes beyond the basics and covers the life-saving options that come into play when these traditional approaches just aren’t cutting it.
The 2-day meeting, which expanded its presence into the west coast for the first time in 2019, will be hosted in two locations this fall. The first edition, taking place October 2-3 in Brooklyn, New York, will be chaired by Dr. Corey Langer, MD, Director of Thoracic Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
Just over a month later, November 20-21, Dr. Langer will join Co-Chair, Edward Garon, MD, Medical Director Thoracic Oncology Program, UCLA Medical Center, Santa Monica, CA, to host the identical, California version of the event. Both chairs look forward to a stimulating discussion:
“There has been immense change in the management of thoracic malignancies over the last decade. Rather than a one-size fits all approach to the management of these diseases, we have come closer to personalizing therapy for individual patients. With that change, comes a newfound need for data on how to manage lung cancer patients with this more personalized approach,” said Garon, when asked to comment on the intention behind the meeting’s makeover.
Have questions on the change? Feel free to reach out to our customer service team. We look forward to hosting you at the meeting this fall.